{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:58:40Z","timestamp":1719928720497},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00104-022-01699-4","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T08:02:54Z","timestamp":1660809774000},"page":"1133-1138","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Peritonealkarzinose des Magenkarzinoms"],"prefix":"10.1007","volume":"93","author":[{"given":"Eva M.","family":"Dobrindt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safak","family":"G\u00fcl-Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Enrique","family":"Alberto Vilchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Gronau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Thuss-Patience","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Rau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"1699_CR1","unstructured":"Robert Koch Institut Zentrum f\u00fcr Krebsregisterdaten. https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Magenkrebs\/magenkrebs_node.html. Zugegriffen: 5. Juni 2022"},{"issue":"3","key":"1699_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung\u00a0H, Ferlay\u00a0J, Siegel\u00a0RL et\u00a0al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1699_CR3","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/jso.26894","volume":"125","author":"H Khan","year":"2022","unstructured":"Khan\u00a0H, Johnston\u00a0FM (2022) Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease. J\u00a0Surg Oncol 125(7):1176\u20131182","journal-title":"J Surg Oncol"},{"issue":"3","key":"1699_CR4","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3748\/wjg.v22.i3.1114","volume":"22","author":"RA Seshadri","year":"2016","unstructured":"Seshadri\u00a0RA, Glehen\u00a0O (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol 22(3):1114\u20131130","journal-title":"World J Gastroenterol"},{"key":"1699_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","volume":"79","author":"J Desiderio","year":"2017","unstructured":"Desiderio\u00a0J, Chao\u00a0J, Melstrom\u00a0L et al (2017) The 30-year experience\u2014A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer 79:1\u201314","journal-title":"Eur J Cancer"},{"issue":"1","key":"1699_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12957-021-02351-x","volume":"19","author":"M Valletti","year":"2021","unstructured":"Valletti\u00a0M, Eshmuminov\u00a0D, Gnecco\u00a0N et\u00a0al (2021) Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology. World J Surg Oncol 19(1):245","journal-title":"World J Surg Oncol"},{"key":"1699_CR7","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF):S3-Leitlinie Magenkarzinom, Langversion 2.0, 2019 AWMF Registernummer: 032\/009OL, http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/magenkarzinom\/ (abgerufen am: 4. Juli 2022)"},{"issue":"9","key":"1699_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/annonc\/mdp047","volume":"20","author":"AFC Okines","year":"2009","unstructured":"Okines\u00a0AFC, Norman\u00a0AR, McCloud\u00a0P et al (2009) Meta-analysis of the REAL\u20112 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5\u2011fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20(9):1529\u20131534","journal-title":"Ann Oncol"},{"issue":"9742","key":"1699_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang\u00a0YJ, Van Cutsem\u00a0E, Feyereislova\u00a0A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a\u00a0phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697","journal-title":"Lancet"},{"issue":"10294","key":"1699_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian\u00a0YY, Shitara\u00a0K, Moehler\u00a0M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a\u00a0randomised, open-label, phase 3 trial. Lancet 398(10294):27\u201340","journal-title":"Lancet"},{"key":"1699_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet\u00a0P, Sugarbaker\u00a0PH (1996) Peritoneal-plasma barrier. Cancer Treat Res 82:53\u201363","journal-title":"Cancer Treat Res"},{"issue":"8","key":"1699_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ejso.2016.03.016","volume":"42","author":"Y Yonemura","year":"2016","unstructured":"Yonemura\u00a0Y, Canbay\u00a0E, Li\u00a0Y, Coccolini\u00a0F et\u00a0al (2016) A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 42(8):1123\u20131131","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"1699_CR13","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1245\/s10434-013-3224-y","volume":"21","author":"RW Randle","year":"2014","unstructured":"Randle\u00a0RW, Swett\u00a0KR, Swords\u00a0DS et\u00a0al (2014) Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 21(5):1474\u20131479","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1699_CR14","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1002\/cam4.2204","volume":"8","author":"R Yarema","year":"2019","unstructured":"Yarema\u00a0R, Mielko\u00a0J, Fetsych\u00a0T et al (2019) Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: a retrospective cooperative central-eastern European study. Cancer Med 8(6):2877\u20132885","journal-title":"Cancer Med"},{"issue":"9","key":"1699_CR15","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1245\/s10434-012-2360-0","volume":"19","author":"E Facchiano","year":"2012","unstructured":"Facchiano\u00a0E, Risio\u00a0D, Kianmanesh\u00a0R, Msika\u00a0S (2012) Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a\u00a0systematic review of the literature. Ann Surg Oncol 19(9):2946\u20132950","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1699_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","volume":"20","author":"G Nadiradze","year":"2016","unstructured":"Nadiradze\u00a0G, Giger-Pabst\u00a0U, Zieren\u00a0J et al (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J\u00a0Gastrointest Surg 20(2):367\u2013373","journal-title":"J Gastrointest Surg"},{"key":"1699_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/pp-2018-0127","volume":"4","author":"PK Garg","year":"2019","unstructured":"Garg\u00a0PK, Jara\u00a0M, Alberto\u00a0M, Rau\u00a0B (2019) The role of pressurized intraperitoneal aerosol chemotherapy in the management of gastric cancer: a\u00a0systematic review. Pleura Peritoneum 4:1","journal-title":"Pleura Peritoneum"},{"key":"1699_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.suronc.2020.05.006","volume":"34","author":"A Di Giorgio","year":"2020","unstructured":"Di Giorgio\u00a0A, Schena\u00a0CA, El Halabieh\u00a0MA et\u00a0al (2020) Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): a\u00a0bidirectional approach for gastric cancer peritoneal metastasis. Surg Oncol 34:270\u2013275","journal-title":"Surg Oncol"},{"issue":"5","key":"1699_CR19","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/jcm11051456","volume":"11","author":"F Gronau","year":"2022","unstructured":"Gronau\u00a0F, Feldbruegge\u00a0L, Oberwittler\u00a0F et\u00a0al (2022) HIPEC in peritoneal metastasis of gastric origin: a systematic review of regimens and techniques. J\u00a0Clin Med 11(5):1456. https:\/\/doi.org\/10.3390\/jcm11051456","journal-title":"J Clin Med"},{"issue":"9","key":"1699_CR20","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen\u00a0O, Gilly\u00a0FN, Arvieux\u00a0C et al (2010) Peritoneal carcinomatosis from gastric cancer: a\u00a0multi-institutional study of 159\u00a0patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370\u20132377","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"1699_CR21","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"P-E Bonnot","year":"2019","unstructured":"Bonnot\u00a0P\u2011E, Piessen\u00a0G, Kepenekian\u00a0V et al (2019) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a\u00a0propensity score analysis. J\u00a0Clin Oncol 37(23):2028\u20132040","journal-title":"J Clin Oncol"},{"key":"1699_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.suronc.2019.01.005","volume":"28","author":"T Hotopp","year":"2019","unstructured":"Hotopp\u00a0T (2019) HIPEC and CRS in peritoneal metastatic gastric cancer\u2014who really benefits? Surg Oncol 28:159\u2013166","journal-title":"Surg Oncol"},{"issue":"6","key":"1699_CR23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"X-J Yang","year":"2011","unstructured":"Yang\u00a0X\u2011J, Huang\u00a0C\u2011Q, Suo\u00a0T et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a\u00a0phase III randomized clinical trial. Ann Surg Oncol 18(6):1575\u20131581","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1699_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jso.23633","volume":"110","author":"U Rudloff","year":"2014","unstructured":"Rudloff\u00a0U, Langan\u00a0RC, Mullinax\u00a0JE et\u00a0al (2014) Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J\u00a0Surg Oncol 110(3):275\u2013284","journal-title":"J Surg Oncol"},{"key":"1699_CR25","doi-asserted-by":"publisher","first-page":"S1040","DOI":"10.1016\/j.annonc.2021.08.1485","volume":"32","author":"B Rau","year":"2021","unstructured":"Rau\u00a0B, Lang\u00a0H, K\u00f6nigsrainer\u00a0A et al (2021) 1376O The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): A randomized multicentre phase III trial (GASTRIPEC-I-trial). Ann Oncol 32:S1040","journal-title":"Ann Oncol"},{"issue":"1","key":"1699_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.amjsurg.2013.04.010","volume":"207","author":"KW Kim","year":"2014","unstructured":"Kim\u00a0KW, Chow\u00a0O, Parikh\u00a0K et\u00a0al (2014) Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. Am J Surg 207(1):78\u201383","journal-title":"Am J Surg"},{"issue":"7","key":"1699_CR27","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ejso.2015.03.231","volume":"41","author":"F Coccolini","year":"2015","unstructured":"Coccolini\u00a0F, Catena\u00a0F, Glehen\u00a0O et al (2015) Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol 41(7):911\u2013919","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"1699_CR28","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1245\/s10434-020-08234-x","volume":"27","author":"A Bhatt","year":"2020","unstructured":"Bhatt\u00a0A, Yonemura\u00a0Y, Mehta\u00a0S et\u00a0al (2020) The pathologic peritoneal cancer index (PCI) strongly differs from the surgical PCI in peritoneal metastases arising from various primary tumors. Ann Surg Oncol 27(8):2985\u20132996","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"1699_CR29","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1245\/s10434-017-6047-4","volume":"24","author":"B Badgwell","year":"2017","unstructured":"Badgwell\u00a0B, Blum\u00a0M, Das\u00a0P et\u00a0al (2017) Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol 24(11):3338\u20133344","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1699_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1245\/s10434-016-5487-6","volume":"24","author":"Y Yonemura","year":"2017","unstructured":"Yonemura\u00a0Y, Ishibashi\u00a0H, Hirano\u00a0M et\u00a0al (2017) Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal\/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol 24(2):478\u2013485","journal-title":"Ann Surg Oncol"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-022-01699-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-022-01699-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-022-01699-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T19:11:23Z","timestamp":1669835483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-022-01699-4"}},"subtitle":["Therapeutische M\u00f6glichkeiten bei Peritonealkarzinose des Magenkarzinoms"],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1699"],"URL":"https:\/\/doi.org\/10.1007\/s00104-022-01699-4","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"25 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.M.\u00a0Dobrindt, S.\u00a0G\u00fcl-Klein, M.E.\u00a0Alberto Vilchez, F.\u00a0Gronau, P.\u00a0Thuss-Patience und B.\u00a0Rau geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}